drugset / Trial / NCT02742987
Clopidogrel Versus Ticagrelor in Type-2 Diabetes
RandomizedCrossoverOpen-labelTreatment
Summary
CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with percutaneous coronary intervention (PCI).
Timeline
- Start
- 2014-03
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clopidogrel | Small molecule | 150 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |